GARS1

Across TCGA pan-cancer cohorts, GARS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GARS1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GARS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GARS1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where GARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.755	0.955	<.001	43	view →
CCRCC	OS	Quartile	III,IV	0.542	0.921	.008	22	view →
PDAC	DFS	Tertile	III,IV	0.381	0.897	.003	15	view →
HNSC	DFS	Median	III,IV	1.000	0.903	.004	14	view →
LSCC	DFS	Median	All	0.920	0.622	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GARS1–LUAD (OS)

Open the LUAD breakdown →